Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching to Biktarvy vs Triumeq in HIV
NCT04155554Phase 3Unknown
- Sponsor
- Azienda Ospedaliera Universitaria Senese
- Start
- Jan 2020
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bictegravir, emtricitabine and tenofovir alafenamide in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by Azienda Ospedaliera Universitaria Senese. Primary endpoint: Global Severity Index (GSI) of Neuropsychiatric Symptoms at 3 months. Status: unknown.
02
Drugs
bictegraviremtricitabinetenofovir alafenamide
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04155554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04155554.